Microvolume Luer Access Device

K212842 · B.Braun Medical, Inc. · FPA · Jan 18, 2022 · General Hospital

Device Facts

• Record ID: K212842
• Device Name: Microvolume Luer Access Device
• Applicant: B.Braun Medical, Inc.
• Product Code: FPA · General Hospital
• Decision Date: Jan 18, 2022
• Decision: SESE
• Submission Type: Traditional
• Regulation: 21 CFR 880.5440
• Device Class: Class 2

Intended Use

The intended use of the Microvolume Luer Access Device is to provide a sterile needle-free fluid pathway for the administration or aspiration of blood, IV therapy, or medications as prescribed by the physician. Fluids are administered to the patient through a catheter or cannula. The device can be utilized as a conduit between two devices, in addition to being used to deliver contrast media via power injection. This is a general use device that may be used for any patient population with consideration given to the adequacy of vascular anatomy and appropriateness for the solution being infused and duration of therapy.

Device Story

Microvolume Luer Access Device (LAD) is a neutral displacement needleless connector; provides sterile needle-free fluid pathway for IV gravity/pump sets, extension sets, and catheters. Input: male luer connector insertion. Operation: valve mechanism allows aspiration, injection, or fluid flow; supports power injection (up to 400 psi, 10ml/sec). Output: fluid delivery/aspiration conduit. Used in clinical settings by healthcare professionals. Benefits: enables needle-free access, reduces needle-stick risk, facilitates contrast media delivery. Device is a 3-piece assembly (body, piston, spike/nut) supplied sterile, single-use.

Clinical Evidence

Bench testing only. No clinical studies performed. Performance testing included flow rate, seal/snap tests, durability, power injection, chemical compatibility (IPA/CHG), microbial ingress, tensile testing, and biocompatibility (ISO 10993-1).

Technological Characteristics

3-piece assembly: Copolyester body, self-lubricating silicone elastomer piston, ABS luer nut, polyethylene male luer lock cover. Neutral displacement valve. Sterile, single-use. Complies with ISO 80369-7 (Luer connectors), ISO 10993-1 (biocompatibility), and ISO 8536 series. No software/electronics.

Indications for Use

Indicated for aspiration, injection, or gravity/pump flow of IV fluids and blood upon insertion of a male luer connector. May be used with power injectors at max pressure 400 psi and max flow rate 10ml/sec. Suitable for any patient population based on vascular anatomy and therapy requirements.

Regulatory Classification

Identification

An intravascular administration set is a device used to administer fluids from a container to a patient's vascular system through a needle or catheter inserted into a vein. The device may include the needle or catheter, tubing, a flow regulator, a drip chamber, an infusion line filter, an I.V. set stopcock, fluid delivery tubing, connectors between parts of the set, a side tube with a cap to serve as an injection site, and a hollow spike to penetrate and connect the tubing to an I.V. bag or other infusion fluid container.

Special Controls

*Classification.* Class II (special controls). The special control for pharmacy compounding systems within this classification is the FDA guidance document entitled “Class II Special Controls Guidance Document: Pharmacy Compounding Systems; Final Guidance for Industry and FDA Reviewers.” Pharmacy compounding systems classified within the intravascular administration set are exempt from the premarket notification procedures in subpart E of this part and subject to the limitations in § 880.9.

Predicate Devices

• Caresite Luer Access Device (K140311)

Reference Devices

• Clave Connector (K970855)

Submission Summary (Full Text)

{0}------------------------------------------------

Image /page/0/Picture/0 description: The image contains the logo of the U.S. Food and Drug Administration (FDA). On the left is the Department of Health & Human Services logo. To the right of that is the FDA logo, which is a blue square with the letters "FDA" in white. To the right of the blue square is the text "U.S. FOOD & DRUG ADMINISTRATION" in blue.

December 18, 2021

B. Braun Medical Inc. Kimberly Smith Sr. Regulatory Affairs Specialist 901 Marcon Blvd. Allentown, Pennsylvania 18109-9341

Re: K212842

Trade/Device Name: Microvolume Luer Access Device Regulation Number: 21 CFR 880.5440 Regulation Name: Intravascular Administration Set Regulatory Class: Class II Product Code: FPA Dated: December 15, 2021 Received: December 17, 2021

#### Dear Kimberly Smith:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. Although this letter refers to your product as a device, please be aware that some cleared products may instead be combination products. The 510(k) Premarket Notification Database located at https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm identifies combination product submissions. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part

{1}------------------------------------------------

801); medical device reporting of medical device-related adverse events) (21 CFR 803) for devices or postmarketing safety reporting (21 CFR 4, Subpart B) for combination products (see https://www.fda.gov/combination-products/guidance-regulatory-information/postmarketing-safety-reportingcombination-products); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820) for devices or current good manufacturing practices (21 CFR 4. Subpart A) for combination products; and, if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to https://www.fda.gov/medical-device-safety/medical-device-reportingmdr-how-report-medical-device-problems.

For comprehensive regulatory information about mediation-emitting products, including information about labeling regulations, please see Device Advice (https://www.fda.gov/medicaldevices/device-advice-comprehensive-regulatory-assistance) and CDRH Learn (https://www.fda.gov/training-and-continuing-education/cdrh-learn). Additionally, you may contact the Division of Industry and Consumer Education (DICE) to ask a question about a specific regulatory topic. See the DICE website (https://www.fda.gov/medical-device-advice-comprehensive-regulatoryassistance/contact-us-division-industry-and-consumer-education-dice) for more information or contact DICE by email ([e-mail]) or phone [phone] or 301-796-7100).

Sincerely,

Gang Peng For Payal Patel Assistant Director DHT3C: Division of Drug Delivery and General Hospital Devices, and Human Factors OHT3: Office of GastroRenal, ObGyn, General Hospital and Urology Devices Office of Product Evaluation and Quality Center for Devices and Radiological Health

Enclosure

{2}------------------------------------------------

# Indications for Use

510(k) Number (if known) K212842

Device Name Microvolume Luer Access Device

#### Indications for Use (Describe)

The Microvolume Luer Access Device is a valve intended for the aspiration, or gravity/pump flow of IV fluids and blood upon insertion of a male luer connector. The Microvolume Luer Access Device may be used with power injectors at a maximum pressure of 400 psi and a maximum flow rate of 10ml/sec.

Type of Use (Select one or both, as applicable)

| Prescription Use (Part 21 CFR 801 Subpart D) | <span style="font-size: 20px;">☑</span> |
|----------------------------------------------|-----------------------------------------|
| Over-The-Counter Use (21 CFR 801 Subpart C) | ☐ |

#### CONTINUE ON A SEPARATE PAGE IF NEEDED.

This section applies only to requirements of the Paperwork Reduction Act of 1995.

#### *DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.*

The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:

> Department of Health and Human Services Food and Drug Administration Office of Chief Information Officer Paperwork Reduction Act (PRA) Staff PRAStaff(@fda.hhs.gov

"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number."

{3}------------------------------------------------

# 510(k) Summary K212842

#### I. Submitter Information

| Name: | B. Braun Medical Inc. |
|-------------------|-----------------------------------------------------|
| Address: | 901 Marcon Boulevard<br>Allentown, PA 18109-9341 |
| Contact Person: | Kimberly Smith<br>Sr. Regulatory Affairs Specialist |
| Telephone Number: | [phone] |
| Fax Number: | [phone] |
| Email | [e-mail] |
| Date Prepared: | January 13, 2022 |

#### II. Device Name and Classification

| Device Trade Name: | Microvolume Luer Access Device |
|----------------------|------------------------------------------------------------------------------------------------------------------------------------------|
| Common Name: | Luer Access Device, Needleless Connector; Needle-free<br>Injection Site; Needle-free Luer Access Device; Needle-free<br>connector; Valve |
| Classification Name: | Intravascular administration set; §21 CFR 880.5440 |
| Regulatory Class | Class II |
| Product Code: | FPA |

## III. Predicate Device

| Device Trade Name: | Caresite Luer Access Device |
|------------------------------|----------------------------------------------------------------------------------|
| Common Name: | Needleless Connector; Needle-free Injection Site; Needle-free Luer Access Device |
| Classification Name: | Intravascular administration set; §21 CFR 880.5440 |
| Regulatory Class | Class II |
| Product Code: | FPA |
| 510(k) Number: | K140311, B. Braun Medical Inc. |
| Reference Device Trade Name: | Clave Connector |
| Classification Name: | Intravascular administration set; §21 CFR 880.5440 |
| 510(k) Number: | K970855, ICU Medical, Inc. |

{4}------------------------------------------------

# IV. Device Description

The Microvolume Luer Access Device (LAD) consists of a body, piston, spike/nut, and a male luer lock cover. The Microvolume LAD is a neutral displacement needleless connector intended to provide needle-free access to IV gravity sets, pump sets and extension sets for the administration of IV fluids and blood. The Microvolume LAD may be used with a power injector. The Microvolume LAD is individually packaged and supplied as a sterile, nonpyrogenic, single use disposable device.

#### V. Indications for Use / Intended Use

### Indications for Use

The Microvolume Luer Access Device is a valve intended for the aspiration, injection, or gravity/pump flow of IV fluids and blood upon insertion of a male luer connector. The Microvolume Luer Access Device may be used with power injectors at a maximum pressure of 400 psi and a maximum flow rate of 10ml/sec.

#### Intended Use

The intended use of the Microvolume Luer Access Device is to provide a sterile needle-free fluid pathway for the administration or aspiration of blood, IV therapy, or medications as prescribed by the physician. Fluids are administered to the patient through a catheter or cannula. The device can be utilized as a conduit between two devices, in addition to being used to deliver contrast media via power injection. This is a general use device that may be used for any patient population with consideration given to the adequacy of vascular anatomy and appropriateness for the solution being infused and duration of therapy.

{5}------------------------------------------------

## VI. Comparison of Technological Characteristics with the Predicate Device

The similarities and differences of the technological characteristics between the predicate and the subject device are summarized below.

Similarities:

- · The subject Microvolume Luer Access Device and the predicate device are identical in their intended use.
- · Mode of fluid delivery is the same for both the predicate and subject devices. Both devices are used for gravity/pump administration.
- · Conditions of use are the same for both the predicate and subject devices. Both devices are used by the same type of healthcare professionals under the same conditions of use.
- · Sterilization method, SAL Level and sterilization cycle are the same for both the predicate and subject devices.
- · Interfaces are similar between the subject device and predicate device. Both devices contain threaded female and male ports intended for use with associated luers.
- · Mechanical and Performance Specifications are similar between the subject device and predicate device. The predicate device performance testing and referenced standards were utilized as a guide to establish the testing for the subject device. The subject device meets all the standards that were met by the predicate. Additional standards were considered for performance testing of the subject device.

#### Differences:

- · Principle of operation is different but achieves the same intended use. The difference does not raise different questions of safety and effectiveness and is evaluated by design verification testing.
- · Physical characteristics and dimensions are different but do not impact the intended use. The differences do not raise different questions on safety and effectiveness and is evaluated by performance testing.
- · Displacement Volume is different but does not impact the intended use. The difference does not raise different questions on safety and effectiveness and is evaluated by performance testing.

{6}------------------------------------------------

| | Proposed Device | Predicate Device | Comparison |
|------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| | Microvolume Luer Access | (K140311) | |
| | Device | Caresite Luer Access Device | |
| Manufacturer | B. Braun Medical Inc. | B. Braun Medical Inc. | Same |
| Intended Use | The intended use of the | The intended use of the | Same |
| | Microvolume Luer Access | Caresite Luer Access Device is | |
| | Device is to provide a sterile | to provide a sterile needle-free | |
| | needle-free fluid pathway for | fluid pathway for the | |
| | the administration or | administration or aspiration of | |
| | aspiration of blood, IV | blood, IV therapy, or | |
| | therapy, or medications as | medications as prescribed by | |
| | prescribed by the physician. | the physician. Fluids are | |
| | Fluids are administered to the | administered to the patient | |
| | patient through a catheter or | through a catheter or cannula. | |
| | cannula. The device can be | The device can be utilized as a | |
| | utilized as a conduit between | conduit between two devices, in | |
| | two devices, in addition to | addition to being used to | |
| | being used to deliver contrast | deliver contrast media via | |
| | media via power injection. | power injection. This device | |
| | This device may be used for | may be used for any patient | |
| | any patient population with | population with consideration | |
| | consideration given to the | given to the adequacy of | |
| | adequacy of vascular | vascular anatomy and | |
| | anatomy and appropriateness | appropriateness for the solution | |
| | for the solution being infused | being infused and duration of | |
| | and duration of therapy. | therapy. | |
| Indications for Use | The Microvolume Luer | The Caresite Luer Access | Different |
| | Access Device is a valve | Device is a valve intended for | Difference in |
| | intended for the aspiration, | the aspiration, injection, or | power injector |
| | injection, or gravity/pump | gravity/pump flow of IV fluids | maximum flow rate |
| | flow of IV fluids and blood | and blood upon insertion of a | falls within the |
| | upon insertion of a male luer | male luer connector. The | indications for use |
| | connector. The Microvolume | Caresite Luer Access Device | of the predicate |
| | Luer Access Device may be | may be used with power | device, therefore; |
| | used with power injectors at a | injectors at a maximum | the two devices |
| | maximum pressure of 400 psi<br>and a maximum flow rate of | pressure of 400 psi and a<br>maximum flow rate of | have equivalent<br>indications for use. |
| | 10ml/sec. | 15ml/sec. | |
| Mode of Fluid Delivery | Gravity/Pump Administration | Gravity/Pump Administration | Same |
| Components of Device | 3-piece assembly containing: | 3-piece assembly containing: | Same |
| | 1. Body | 1. Body | |
| | 2. Piston | 2. Piston | |
| | 3. Luer Nut | 3. Luer Nut | |
| | 4. Male luer lock vented | 4. Male luer lock vented cover | |
| | cover | | |
| Summary of nonclinical<br>tests for determination<br>of substantial<br>equivalence | • Flow Rate & Capacity<br>Attributes<br>• Seal and Snap Tests<br>• Durability Testing<br>• Seal Tests - Post<br>Durability<br>• Power Injection<br>• 7 Day IPA & CHG<br>Compatibility<br>• IPA Exposure, Infusate<br>Compatibility<br>• Duration & Connector<br>Removal<br>• ISO 80369-7 Compliance<br>Testing<br>• Associate Male ID Testing<br>• 7 Day Disinfection Cap<br>Compatibility with Swab<br>Cap, Curos Jet, and<br>CareCap. Disinfection Cap<br>Valve Activation<br>• Particulate Contamination<br>• Cap Assessment after Ship<br>Test<br>• Mechanical Hemolysis<br>• Microbial Ingress Testing<br>• Tensile Testing<br>• Real-Time Aging<br>• Displacement Volume<br>• Flushability<br>• Ship Testing | • Flow Rate & Capacity<br>Attributes<br>• Seal and Weld Tests<br>• Durability Testing<br>• Seal Tests - Post Durability<br>• Power Injection<br>• 4 Day IPA & CHG<br>Compatibility<br>• IPA Exposure, Infusate<br>Compatibility<br>• Duration<br>• ISO 594 Compliance Testing<br>• Associate Device Testing<br>• Mechanical Hemolysis<br>• Microbial Ingress Testing<br>• Flushability<br>• Ship Testing | Different<br>The additional<br>nonclinical tests do<br>not raise different<br>questions on safety<br>and effectiveness,<br>as demonstrated by<br>performance<br>testing. |
| Physical Characteristics | Male Luer ID = 0.0673 in.<br>Male Luer OD = 0.1565in.<br>w/0.060 in/in taper<br>Female ID = 0.1669in.<br>Priming Volume = 0.0345 mL,<br>average<br>Residual Volume = 0.052 mL,<br>average | Male Luer ID = 0.080 in.<br>Male Luer OD = 0.1565 in.<br>w/0.060 in/in taper<br>Female ID = 0.1669 in.<br>Priming Volume = 0.22 mL,<br>average<br>Residual Volume = 0.20 mL,<br>average | Different<br>The physical<br>characteristics do<br>not raise different<br>questions on safety<br>and effectiveness, as<br>demonstrated by<br>performance testing. |
| Materials | • Body - Copolyester<br>• Piston - Silicone Elastomer,<br>Self-lubricating<br>• Luer Nut - ABS<br>• Male Luer Lock Vented<br>Cover - Polyethylene | • Body - Polycarbonate<br>• Piston - Silicone Elastomer,<br>Self-lubricating<br>• Luer Nut - Polycarbonate<br>• Male Luer Lock Vented Cover<br>- Polyethylene | Different<br>The difference in<br>materials do not<br>raise different<br>questions on safety<br>and effectiveness as<br>demonstrated by<br>performance testing<br>and<br>biocompatibility. |
| Patient Contact<br>category/duration | Externally Communicating,<br>Blood Path Indirect<br>prolonged exposure | Externally Communicating,<br>Blood Path Indirect<br>prolonged exposure…